MediWound Ltd
Graphique
Bon à savoir : L’investissement en actions présente un potentiel de rendement à long terme, mais implique également un risque de perte, pouvant aller jusqu’à la totalité du capital investi. Les performances passées ne préjugent pas des performances futures. Les données fournies par des sources externes n’ont pas été modifiées par Saxo. Voir la clause de non-responsabilité
À propos MediWound Ltd
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
/ 